Clinical Policy Title:	pirtobrutinib
Policy Number:	RxA.794
Drug(s) Applied:	Jaypirca™
Original Policy Date:	04/13/2023
Last Review Date:	10/19/2023
Line of Business Policy Applies to:	All lines of business (except Medicare)

Criteria

I. Initial Approval Criteria

A. Mantle cell lymphoma (MCL) (must meet all):

1. Diagnosis of relapsed or refractory mantle cell lymphoma (MCL);
2. Age ≥ 18 years;
3. Member must have histologically confirmed MCL;
4. Trial and failure of at least two prior therapies, one of which was with a BTKi;
5. Member must have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2 ;
6. Request meets one of the following (a or b):*
   a. Dose does not exceed 200 mg orally once daily;
   b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).

   *Prescribed regimen must be FDA-approved or recommended by NCCN.

Approval Duration
Commercial: 2 months
Medicaid: 2 months

II. Continued Therapy Approval

A. Mantle cell lymphoma (MCL) (must meet all):

1. Member is currently receiving medication that has been authorized by RxAdvance or the member has met initial approval criteria listed in this policy;
2. Member is responding positively to therapy;
3. If request is for a dose increase, request meets one of the following (a or b):*
   a. New dose does not exceed 200 mg orally once daily;
   b. New dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).

   *Prescribed regimen must be FDA-approved or recommended by NCCN

Approval Duration
Commercial: 6 months
Medicaid: 6 months

References

1. National Comprehensive Cancer Network Guidelines. B-Cell Lymphomas. Version 2.2023. Available at: https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf. Accessed March 20, 2023.

Review/Revision History	Review/Revision Date	P&T Approval Date
Policy established.	03/20/2023	04/13/2023
Policy was reviewed.	10/19/2023	10/19/2023